论文部分内容阅读
伏立康唑是广谱三唑类抗真菌药,临床上广泛用于各种侵袭性霉菌感染的治疗。为制定伏立康唑在青少年中的适宜给药剂量,本研究选取26例年龄12～17岁免疫缺陷的青少年进行伏立康唑的药动学研究和安全性评价。受试者第1天静脉滴注伏立康唑6 mg/kg,继以每日静脉滴注4 mg/kg共6 d,之后口服本品每12小时300 mg,6.5 d。采用LC/MS/MS法测定伏立康唑的血药浓度,用非房室模型计算主要药动学参数(Cmax,Tmax,Cmin和AUC0-12),并与给予
Voriconazole is a broad-spectrum triazole antifungal agent that is clinically widely used in the treatment of various invasive fungal infections. In order to make the dose of voriconazole suitable for adolescents, we studied the pharmacokinetics and safety evaluation of voriconazole in 26 adolescents aged 12 to 17 with immunodeficiency. Subjects were intravenously administered voriconazole 6 mg / kg on day 1, followed by daily intravenous infusion of 4 mg / kg for 6 days, after oral administration of 300 mg, 6.5 d every 12 hours. The plasma concentrations of voriconazole were determined by LC / MS / MS. The main pharmacokinetic parameters (Cmax, Tmax, Cmin and AUC0-12) were calculated by non-compartmental model and compared with the administration